References
- Ettinger D. S. Metabolic complications in cancer patients. ICSCO Rev 1990; 3: 1–3
- Rubens R. D. The clinical problems of hypercalcaemia and bone metastases. The management of bone metastases and hypercalcaemia by osteoclast inhibition, R. D. Rubens. Hogrefe & Huber Publishers, Toronto 1990; 9–11
- Nešković-Konstantinović Z, Mitrović L, Petrović J, Stamatović L, Ristović Z. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of dissodium pamidronate adapted to the initial level of calcaemia. Support Care Cancer 1995; 3: 422–4
- Body J. J. Medical treatment of tumour induced hypercal-caemia and tumour induced osteolysis: challenges for future research. Support Care Cancer 1993; 1: 26–33
- Mundy G. R. Mechanisms of osteolytic bone destruction. Bone 1991; 12(Suppl. 1)S1–S6
- Dodwell D. J., Howell A. The systemic treatment of bone metastases. Bone metastases -diagnosis and treatment, R. D. Rubens, I. Fogelman. Springer-Verlag, London 1991; 121–47
- Tattersall M. H. N. Hypercalcaemia: historical perspectives and present management. Support Care Cancer 1993; 1: 19–25
- Hosking D. J., Cowley A., Bucknall C. A. Rehydration in the treatment of severe hypercalcaemia. Quart J Med 1982; 200: 473–81
- Body J. J., Borkowski A., Cleeren A., Bijvoet O. L. M. Treatment of malignancy-associated hypercalcaemia with intravenous aminohydroxypropylidene disphosphonate. Clin Oncol 1986; 4: 1177–83
- Ralston S. H., Gallacher S. J., Patel U., et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2: 1180–2
- Sleeboom H. P., Bijvoet O. L., Van Oosterom A. T., Gleed J. H., O'Riordan J. L. H. Comparison of intravenous (3-amino-1-hy-droxypropylidene)-l 1-bisphosphonate and volume repletion in tumour induced hypercalcaemia. Lancet 1983; 2: 239–43
- Ralston S. H. Pathogenesis and management of cancer-associated hypercalcaemia. Bone metastases-diagnosis and treatment, R. D. Rubens, I. Fogelman. Springer-Verlag, London 1991; 146–69
- Kanis J. A., McCloskey E. V., Traube T., O'Rourke N. Rational for the use of bisphosphonates in bone metastases. Bone 1991; 12((Suppl. 1))S13–S18
- Rubens R. D. Nature of metastatic bone disease. Metastatic bone disease. Fundamental and clinical aspects, I. J. Diel, M. Kaufmann, G. Bastert. Springer-Verlag, Berlin, Heidelberg 1994; 12–19
- Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–44